Endonovo Therapeutics (OTCQB: ENDV) today announced
its collaboration with a Stanford University sponsored Orthopedic Shoulder and
Knee Study to determine benefits of Endonovo’s tPEMF SofPulse(R) on pain,
medication levels and physical function post-operatively. According to the
update, the study will evaluate 76 patients with Active and Sham Comparator
groups, measured by visual analog scale (“VAS”), at 10 days after, and will
allow surgeons to determine postoperative efficacy of Endonovo’s SofPulse(R)
tPEMF portable device. “The study will allow surgeons to determine if PEMF
SofPulse(R) therapy is beneficial in reducing patient-reported post-operative
pain,” Endonovo CMO, Dr. Nev Zubcevik DO, said in the news release. “Surgeons
will be able to make observations on the amount of pain medication taken daily
and the physical function outcome scores after surgery and PEMF treatment. Past
published clinical efficacy studies for tPEMF SofPulse(R) have shown 2.2X
reduction of post-op use of narcotics at 48 hours, 300% reduction of pain
scores which relates to nearly a three times faster reduction in the need for
pain medication post-op and 275% reduction in inflammation and swelling at 18
hours postoperatively.”
To view the full press release, visit http://ibn.fm/HNsJ8
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of noninvasive
wearable Electroceuticals(R) therapeutic devices. The Company’s current
portfolio of commercial and clinical-stage wearable Electroceuticals(R)
therapeutic devices addresses wound healing, pain, post-surgical pain and
edema, cardiovascular disease, chronic kidney disease, and central nervous
system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute
concussions, post-concussion syndrome and multiple sclerosis. The Company’s
noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses
pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE
marked for the palliative treatment of soft tissue injuries and post-operative
pain and edema and has CMS national coverage for the treatment of chronic
wounds. The Company’s current portfolio of preclinical-stage
Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver
disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral
artery disease (“PAD”), and ischemic stroke. The Company’s noninvasive,
wearable Electroceuticals(R) therapeutic devices work by restoring key
electrochemical processes that initiate anti-inflammatory and growth factor
cascades necessary for healing to occur. For more information, visit www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment